Access restrictions were established for this page. If you see this message, you have no access to this page.
سامان رنجبر (بحث | مشارکتها) بدون خلاصۀ ویرایش |
سامان رنجبر (بحث | مشارکتها) |
||
| (۶ نسخهٔ میانیِ ایجادشده توسط همین کاربر نشان داده نشد) | |||
| خط ۳۳: | خط ۳۳: | ||
Thiamine, as a water-soluble vitamin, plays a crucial purpose in the metabolism of energy, making it an essential component of the diet. The protective effects of thiamine against diabetic vascular problems have been well documented. | Thiamine, as a water-soluble vitamin, plays a crucial purpose in the metabolism of energy, making it an essential component of the diet. The protective effects of thiamine against diabetic vascular problems have been well documented. | ||
However, delayed absorption and decreased bioavailability are major limiting factors for its clinical use. To overcome this issue, lipid-soluble thiamine derivatives (allithiamines) were developed. Among the many synthetic lipophilic products of thiamine, benfotiamine (BFT) is regarded as the first choice based on its safety and clinical efficacy studies<ref>[https://pubmed.ncbi.nlm.nih.gov/9248773 Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate ]</ref> | |||
Benfotiamine blocks several hyperglycemia‐induced pathways of tissue damage in the retina and causes a reduction in superoxide production | . | ||
High-dose benfotiamine (up to 600 mg/day) has been shown in short-term studies (3–12 weeks) to improve symptom scores in diabetic polyneuropathy<ref>[https://pubmed.ncbi.nlm.nih.gov/15726875 Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) ]</ref><ref>[ https://pubmed.ncbi.nlm.nih.gov/18473286 Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study ]</ref> | |||
Benfotiamine blocks several hyperglycemia‐induced pathways of tissue damage in the retina and causes a reduction in superoxide production. | |||
<ref>[https://pubmed.ncbi.nlm.nih.gov/15726875 Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) ]</ref> | |||
Benfotiamine has direct antioxidant properties as well<ref>[https://pubmed.ncbi.nlm.nih.gov/18384109 Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro ]</ref>. | |||
It has been shown that treatment with benfotiamine avoids functional and structural changes in the retina. Benfotiamine has been demonstrated that benfotiamine protects against non-diabetic vascular damage<ref>[ https://pubmed.ncbi.nlm.nih.gov/20107192 Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway]</ref> | |||
In a recent study, benfotiamine was shown to prevent cardiac dysfunction in diabetes through modulating PI3 kinase‐AKT pathway <ref>[https://pubmed.ncbi.nlm.nih.gov/20107192 Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway ]</ref> | |||
Therefore, by affecting oxidative stress, a common pathogenetic pathway, benfotiamine might potentially prevent multiple chronic diabetes problems <ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015539/ Preventive effects of benfotiamine in chronic diabetic complications ]</ref>. | |||
Ramin Taghizadeh | Ramin Taghizadeh | ||